Stem cells are building blocks of the immune system and blood, and they have the ability to develop into other cell types, in order to help in repairing tissues, organs, and blood vessels. They are also used in the treatment of various disease. The ability of stem cells to regenerate has led to the development of various treatments with it, to cure various genetic and auto-immune diseases and disorders. Cord blood stem cells have been used to treat nearly 80 diseases including numerous types of malignancies, anemia, inherited metabolic disorders, and deficiencies of the immune system. Moreover, with the advancement in regenerative medicine, individuals of all ages can benefit from stem cell therapy in the near future. This is expected to augment the market growth. Stem cell banking market is expected to gain significant traction, owing to factors such as rising awareness about the therapeutic importance of stem cells, growing number of clinical trials for products that are stem cell-based, and increasing research grants and public-private funding for the development of novel treatments that are stem cell-based.
Market Dynamics
Supportive products for stem cell research initiatives are being launched in order to introduce personalized therapy and prevent stem cell transplant side effects. This is expected to accelerate the market growth. For instance, on July 21, 2021, Kadmon Pharmaceuticals, LLC, a biopharmaceutical company has received approval from the U.S. Food and Drug administration (FDA) for Rezurock (belumosudil), a treatment indicated for chronic graft-versus-host disease (cGVHD), a condition caused due to allogeneic stem cell transplantation in adults and children older than 12 years. This acquisition is expected to increase the use of stem cell processing for medical purposes.
Key features of the study:
- This report provides an in-depth analysis of the global stem cell banking market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global stem cell banking market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Stem Cyte, Inc., CRYO-CELL INTERNATIONAL, INC., ViaCord, Cord Blood Registry, SmartCells, Inc., LifeCell International Pvt. Ltd., Cryoviva Biotech Pvt. Ltd., Cryo Stemcell, Reliance Life Sciences, and Transcell Biolife Pvt. Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global stem cell banking market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global stem cell banking market
Detailed Segmentation:
- Global Stem Cell Banking Market, By Source Type:
- Cord Blood
- Cord Tissue
- Global Stem Cell Banking Market, By Service Type:
- Collection and Transportation
- Processing
- Analysis
- Storage
- Global Stem Cell Banking Market, By Application:
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- Global Stem Cell Banking Market, By Region:
- North America
- Cord Blood
- Cord Tissue
- Collection and Transportation
- Processing
- Analysis
- Storage
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- U.S.
- Canada
- Latin America
- Cord Blood
- Cord Tissue
- Collection and Transportation
- Processing
- Analysis
- Storage
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Cord Blood
- Cord Tissue
- Collection and Transportation
- Processing
- Analysis
- Storage
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Cord Blood
- Cord Tissue
- Collection and Transportation
- Processing
- Analysis
- Storage
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Cord Blood
- Cord Tissue
- Collection and Transportation
- Processing
- Analysis
- Storage
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- GCC
- Israel
- Rest of Middle East
- Africa
- Cord Blood
- Cord Tissue
- Collection and Transportation
- Processing
- Analysis
- Storage
- Leukemia
- Diabetes
- Lymphoma
- Cerebral Palsy
- Thalassemia
- Others
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Stem Cyte, Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CRYO-CELL INTERNATIONAL, INC.
- ViaCord
- Cord Blood Registry
- SmartCells, Inc.
- LifeCell International Pvt. Ltd.
- Cryoviva Biotech Pvt. Ltd.
- Cryo Stemcell
- Reliance Life Sciences
- Transcell Biolife Pvt. Ltd.
"*" marked represents similar segmentation in other categories in the respective section.